skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection

Abstract

Abstract Objectives The aim of this study was to evaluate the efficacy of dalbavancin against MRSA biofilm-related infection in orthopaedic implants in vivo. Methods One MRSA strain isolated from human osteomyelitis was used to promote biofilm formation on the surface of screws. The implants were inserted in the proximal tibia under general anaesthesia. Thirty-nine Wistar rats were divided into three groups [control group (no treatment), Group 1 (7 days of treatment) and Group 2 (14 days of treatment)]; both treatment groups were administered dalbavancin intraperitoneally and euthanized after treatment. cfu of bacteria present in both the tibia and the implant were quantified. The infection severity was assessed by histopathology and scored from 0 (no infection) to 4 (severe infection). Results The high number of cfu/g and cfu/mL present in the control group indicated a well-established infection. There was a significant reduction in cfu in rats treated with dalbavancin both in the tibia (2.8 × 105 cfu/g) and the implant (1.1 × 106 cfu/mL) in Group 1 (1.8 × 103 cfu/g and 2.4 × 105 cfu/mL, respectively) and in Group 2 (8.2 cfu/g and 8.2 × 103 cfu/mL, respectively). Most animals from the control group presented an infection scored as 3 (severe). At the end of the experiment, most rats from Groups 1 and 2 presented an infection scoredmore » as 2 (moderate) and 0 (no infection), respectively. Conclusions Although there was a marked decrease in cfu number, signs of biofilm-induced infection prevailed after 14 days of treatment. Further studies should be carried out to evaluate the potential of dalbavancin in the treatment of bone and orthopaedic implant-associated MRSA infections.« less

Authors:
ORCiD logo [1];  [2];  [2];  [3];  [4];  [5];  [3];  [3];  [6];  [7];  [8]
  1. Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal, Department of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal, Functional Genomics and Proteomics Unit, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal, Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, Lisboa, Caparica, Portugal
  2. Angelini, Medical Department, C. Quebrada-Dafundo, Portugal
  3. Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal, CECAV, Vila Real, Portugal
  4. Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal, Department of Zootechnics, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal
  5. Department of Zootechnics, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal
  6. BIOSCOPE Group, LAQV@REQUIMTE, Chemistry Department, Faculty of Science and Technology, NOVA University of Lisbon, Almada, Portugal, Proteomass Scientific Society, Costa de Caparica, Portugal
  7. Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal, Department of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal, Functional Genomics and Proteomics Unit, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal, Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, Lisboa, Caparica, Portugal, Department of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal
  8. Microbiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), Vila Real, Portugal, Associated Laboratory for Green Chemistry (LAQV-REQUIMTE), University NOVA of Lisboa, Lisboa, Caparica, Portugal
Publication Date:
Sponsoring Org.:
USDOE Office of Nuclear Energy (NE), Nuclear Fuel Cycle and Supply Chain
OSTI Identifier:
1619442
Grant/Contract Number:  
UID/QUI/50006/2019; SFRH/BD/137947/2018
Resource Type:
Published Article
Journal Name:
Journal of Antimicrobial Chemotherapy
Additional Journal Information:
Journal Name: Journal of Antimicrobial Chemotherapy; Journal ID: ISSN 0305-7453
Publisher:
Oxford University Press
Country of Publication:
United Kingdom
Language:
English

Citation Formats

Silva, Vanessa, Antão, H. Sofia, Guimarães, João, Prada, Justina, Pires, Isabel, Martins, Ângela, Maltez, Luís, Pereira, José E., Capelo, José L., Igrejas, Gilberto, and Poeta, Patrícia. Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection. United Kingdom: N. p., 2020. Web. doi:10.1093/jac/dkaa163.
Silva, Vanessa, Antão, H. Sofia, Guimarães, João, Prada, Justina, Pires, Isabel, Martins, Ângela, Maltez, Luís, Pereira, José E., Capelo, José L., Igrejas, Gilberto, & Poeta, Patrícia. Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection. United Kingdom. doi:https://doi.org/10.1093/jac/dkaa163
Silva, Vanessa, Antão, H. Sofia, Guimarães, João, Prada, Justina, Pires, Isabel, Martins, Ângela, Maltez, Luís, Pereira, José E., Capelo, José L., Igrejas, Gilberto, and Poeta, Patrícia. Sun . "Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection". United Kingdom. doi:https://doi.org/10.1093/jac/dkaa163.
@article{osti_1619442,
title = {Efficacy of dalbavancin against MRSA biofilms in a rat model of orthopaedic implant-associated infection},
author = {Silva, Vanessa and Antão, H. Sofia and Guimarães, João and Prada, Justina and Pires, Isabel and Martins, Ângela and Maltez, Luís and Pereira, José E. and Capelo, José L. and Igrejas, Gilberto and Poeta, Patrícia},
abstractNote = {Abstract Objectives The aim of this study was to evaluate the efficacy of dalbavancin against MRSA biofilm-related infection in orthopaedic implants in vivo. Methods One MRSA strain isolated from human osteomyelitis was used to promote biofilm formation on the surface of screws. The implants were inserted in the proximal tibia under general anaesthesia. Thirty-nine Wistar rats were divided into three groups [control group (no treatment), Group 1 (7 days of treatment) and Group 2 (14 days of treatment)]; both treatment groups were administered dalbavancin intraperitoneally and euthanized after treatment. cfu of bacteria present in both the tibia and the implant were quantified. The infection severity was assessed by histopathology and scored from 0 (no infection) to 4 (severe infection). Results The high number of cfu/g and cfu/mL present in the control group indicated a well-established infection. There was a significant reduction in cfu in rats treated with dalbavancin both in the tibia (2.8 × 105 cfu/g) and the implant (1.1 × 106 cfu/mL) in Group 1 (1.8 × 103 cfu/g and 2.4 × 105 cfu/mL, respectively) and in Group 2 (8.2 cfu/g and 8.2 × 103 cfu/mL, respectively). Most animals from the control group presented an infection scored as 3 (severe). At the end of the experiment, most rats from Groups 1 and 2 presented an infection scored as 2 (moderate) and 0 (no infection), respectively. Conclusions Although there was a marked decrease in cfu number, signs of biofilm-induced infection prevailed after 14 days of treatment. Further studies should be carried out to evaluate the potential of dalbavancin in the treatment of bone and orthopaedic implant-associated MRSA infections.},
doi = {10.1093/jac/dkaa163},
journal = {Journal of Antimicrobial Chemotherapy},
number = ,
volume = ,
place = {United Kingdom},
year = {2020},
month = {5}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
DOI: https://doi.org/10.1093/jac/dkaa163

Save / Share:

Works referenced in this record:

Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue
journal, January 2015

  • Dunne, Michael W.; Puttagunta, Sailaja; Sprenger, Craig R.
  • Antimicrobial Agents and Chemotherapy, Vol. 59, Issue 4
  • DOI: 10.1128/AAC.04550-14

First report of linezolid-resistant cfr-positive methicillin-resistant Staphylococcus aureus in humans in Portugal
journal, June 2019

  • Silva, Vanessa; Almeida, Francisco; Silva, Adriana
  • Journal of Global Antimicrobial Resistance, Vol. 17
  • DOI: 10.1016/j.jgar.2019.05.017

The Limitations of In Vitro Experimentation in Understanding Biofilms and Chronic Infection
journal, November 2015

  • Roberts, Aled E. L.; Kragh, Kasper N.; Bjarnsholt, Thomas
  • Journal of Molecular Biology, Vol. 427, Issue 23
  • DOI: 10.1016/j.jmb.2015.09.002

The influence of skeletal implants on incidence of infection. Experiments in a canine model.
journal, January 1985


Application of a Rat Osteomyelitis Model to Comparein Vivoandin Vitrothe Antibiotic Efficacy against Bacteria with High Capacity to Form Biofilms
journal, October 1998

  • Gracia, E.; Laclériga, A.; Monzón, M.
  • Journal of Surgical Research, Vol. 79, Issue 2
  • DOI: 10.1006/jsre.1998.5416

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model
journal, June 2018


A simple infection model using pre-colonized implants to reproduce rat chronicStaphylococcus aureus osteomyelitis and study antibiotic treatment
journal, September 2001


Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis
journal, October 2015

  • Barnea, Yoav; Lerner, Anat; Aizic, Asaf
  • Journal of Antimicrobial Chemotherapy, Vol. 71, Issue 2
  • DOI: 10.1093/jac/dkv357

Pharmacokinetic-Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic
journal, September 2008

  • Dowell, James A.; Goldstein, Beth P.; Buckwalter, Mary
  • The Journal of Clinical Pharmacology, Vol. 48, Issue 9
  • DOI: 10.1177/0091270008321273

Investigation of methicillin-resistant Staphylococcus aureus among clinical isolates from humans and animals by culture methods and multiplex PCR
journal, October 2018


Biofilm dispersal of community-associated methicillin-resistant Staphylococcus aureus on orthopedic implant material: DISPERSAL OF MRSA BIOFILMS
journal, July 2009

  • Lauderdale, Katherine J.; Malone, Cheryl L.; Boles, Blaise R.
  • Journal of Orthopaedic Research, Vol. 28, Issue 1
  • DOI: 10.1002/jor.20943

Antibiotic resistance of bacterial biofilms
journal, April 2010


Antibiotic Discovery: Combatting Bacterial Resistance in Cells and in Biofilm Communities
journal, March 2015


Molecular mechanisms of antimicrobial tolerance and resistance in bacterial and fungal biofilms
journal, June 2014


In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections
journal, August 2016

  • Fernández, Javier; Greenwood-Quaintance, Kerryl E.; Patel, Robin
  • Diagnostic Microbiology and Infectious Disease, Vol. 85, Issue 4
  • DOI: 10.1016/j.diagmicrobio.2016.05.009

Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci
journal, January 2018


Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE)
journal, November 2016

  • Knafl, D.; Tobudic, S.; Cheng, S. C.
  • European Journal of Clinical Microbiology & Infectious Diseases, Vol. 36, Issue 4
  • DOI: 10.1007/s10096-016-2845-z

Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility
journal, March 2019


In Vitro and In Vivo Biofilm Characterization of Methicillin-Resistant Staphylococcus aureus from Patients Associated with Pharyngitis Infection
journal, January 2016

  • Gowrishankar, Shanmugaraj; Kamaladevi, Arumugam; Balamurugan, Krishnaswamy
  • BioMed Research International, Vol. 2016
  • DOI: 10.1155/2016/1289157

New agents approved for treatment of acute staphylococcal skin infections
journal, January 2016

  • Tatarkiewicz, Jan; Staniszewska, Anna; Bujalska-Zadrożny, Magdalena
  • Archives of Medical Science, Vol. 6
  • DOI: 10.5114/aoms.2016.59838

Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials
journal, September 2012


Engineering Approaches for the Detection and Control of Orthopaedic Biofilm Infections
journal, January 2005


The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery
journal, November 2017


Bacterial biofilm formation on implantable devices and approaches to its treatment and prevention
journal, December 2018


Biofilm in Implant Infections: Its Production and Regulation
journal, November 2005

  • Costerton, J. W.; Montanaro, L.; Arciola, C. R.
  • The International Journal of Artificial Organs, Vol. 28, Issue 11
  • DOI: 10.1177/039139880502801103

Recommendations for design and conduct of preclinical in vivo studies of orthopedic device-related infection: IN VIVO STUDIES OF ODRI
journal, February 2019

  • Moriarty, T. Fintan; Harris, Llinos G.; Mooney, Robert A.
  • Journal of Orthopaedic Research®, Vol. 37, Issue 2
  • DOI: 10.1002/jor.24230

Daptomycin, Fosfomycin, or Both for Treatment of Methicillin-Resistant Staphylococcus aureus Osteomyelitis in an Experimental Rat Model
journal, August 2011

  • Poeppl, W.; Tobudic, S.; Lingscheid, T.
  • Antimicrobial Agents and Chemotherapy, Vol. 55, Issue 11
  • DOI: 10.1128/AAC.00584-11

Etiology of Implant Orthopedic Infections: A Survey on 1027 Clinical Isolates
journal, November 2005

  • Arciola, C. R.; An, Y. H.; Campoccia, D.
  • The International Journal of Artificial Organs, Vol. 28, Issue 11
  • DOI: 10.1177/039139880502801106